News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Repare Therapeutics Inc.
< Previous
1
2
Next >
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
August 09, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
June 08, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
June 07, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
June 06, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights
June 02, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
May 09, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
April 28, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
April 18, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306
March 14, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
February 02, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals
January 19, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
December 19, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 09, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
November 07, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
September 07, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
August 04, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 07, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
June 01, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
May 09, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
May 05, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification
April 20, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting
April 11, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting
April 08, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
February 03, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022
January 07, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development
January 05, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors
December 21, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.